Clinical Trial Update: Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

View source ↗

Summary

A completed post-marketing surveillance trial evaluating intravenous panitumumab at 100 mg and 400 mg in unresectable, advanced, or recurrent colorectal cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Takeda | Conditions: Advanced or Recurrent Colorectal Cancer | Status: COMPLETED | Results posted: 2017-04-06